DK1643999T3 - Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes - Google Patents

Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes

Info

Publication number
DK1643999T3
DK1643999T3 DK04755763.2T DK04755763T DK1643999T3 DK 1643999 T3 DK1643999 T3 DK 1643999T3 DK 04755763 T DK04755763 T DK 04755763T DK 1643999 T3 DK1643999 T3 DK 1643999T3
Authority
DK
Denmark
Prior art keywords
pyridoxamine
diabetes
treatment
type
diabetic nephropathy
Prior art date
Application number
DK04755763.2T
Other languages
English (en)
Inventor
Thorsten Degenhardt
Robert Schotzinger
J Wesley Fox
Original Assignee
Nephrogenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nephrogenex Inc filed Critical Nephrogenex Inc
Application granted granted Critical
Publication of DK1643999T3 publication Critical patent/DK1643999T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK04755763.2T 2003-06-20 2004-06-18 Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes DK1643999T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48003203P 2003-06-20 2003-06-20
US56206204P 2004-04-14 2004-04-14
PCT/US2004/019808 WO2004112788A1 (en) 2003-06-20 2004-06-18 Pyridoxamine for the treatment of diabetic kidney disease

Publications (1)

Publication Number Publication Date
DK1643999T3 true DK1643999T3 (da) 2012-01-02

Family

ID=33544423

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04755763.2T DK1643999T3 (da) 2003-06-20 2004-06-18 Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes

Country Status (10)

Country Link
US (3) US20050014799A1 (da)
EP (1) EP1643999B8 (da)
AT (1) ATE526023T1 (da)
CA (1) CA2529538C (da)
CY (1) CY1112184T1 (da)
DK (1) DK1643999T3 (da)
ES (1) ES2374399T3 (da)
PL (1) PL1643999T3 (da)
PT (1) PT1643999E (da)
WO (1) WO2004112788A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750209B1 (en) * 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US7214799B2 (en) * 2004-02-09 2007-05-08 Biostratum, Inc. Methods for the synthesis of pyridoxamine
CN100558359C (zh) * 2004-09-06 2009-11-11 兴和株式会社 肾小球病治疗剂
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
WO2008070778A2 (en) * 2006-12-06 2008-06-12 Nephrogenex Inc. Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
CA2837234A1 (en) * 2010-05-25 2011-12-01 Eric Kuhrts Stable formulations of fatty acids
US9522884B2 (en) * 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254572A (en) * 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6740668B1 (en) * 1995-08-28 2004-05-25 Kansas University Medical Center Methods for inhibiting diabetic complications
US6716858B1 (en) * 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6436969B1 (en) * 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
US6750209B1 (en) * 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6730686B1 (en) * 1995-09-12 2004-05-04 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US20030013746A1 (en) * 1996-09-10 2003-01-16 University Of Kansas Medical Center. Advanced glycation end-product intermediaries and post-amadori inhibition
US7030146B2 (en) * 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
ES2197689T3 (es) * 1998-10-22 2004-01-01 University Of South Carolina Procedimientos para inhibir complicaciones diabeticas.
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AU5840200A (en) 1999-07-13 2001-01-30 Medicure Inc. Treatment of diabetes and related pathologies
EP1872797A3 (en) 1999-08-24 2008-04-02 Medicure International Inc. Treatment of cardiovascular and related pathologies
WO2002036109A2 (en) * 2000-11-02 2002-05-10 University Of South Carolina Use of pyridoxamine for the treatment and inhibition of obesity-related complications
WO2002039994A2 (en) * 2000-11-20 2002-05-23 University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease

Also Published As

Publication number Publication date
EP1643999B8 (en) 2012-03-14
CA2529538C (en) 2011-04-26
US8067444B2 (en) 2011-11-29
ES2374399T3 (es) 2012-02-16
PT1643999E (pt) 2012-01-09
EP1643999A1 (en) 2006-04-12
US20060287367A1 (en) 2006-12-21
EP1643999B1 (en) 2011-09-28
PL1643999T3 (pl) 2012-02-29
WO2004112788A1 (en) 2004-12-29
CY1112184T1 (el) 2015-12-09
ATE526023T1 (de) 2011-10-15
CA2529538A1 (en) 2004-12-29
US20080119525A1 (en) 2008-05-22
US20050014799A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
EA200701175A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
DE50008336D1 (de) Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
EP1651195A4 (en) PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
HK1068606A1 (en) Novel aminobenzoephenones
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
ZA200303037B (en) Herbal pharmaceutical composition for treatment of HIV/Aids patients.
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
HK1097762A1 (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
AU2003286726A8 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
MXPA02006511A (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
ATE499945T1 (de) Pharmazeutische zusammensetzung zur behandlung von invasiver lungenaspergillose
DE602005011029D1 (de) Therapeutisches mittel zur behandlung von plasmazellneoplasien
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck